Proteomics International Laboratories Ltd (PIQ.AX) US update - PromarkerD Licensing Negotiations

Proteomics International Laboratories Ltd (ASX:PIQ) advises that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company's PromarkerD predictive test for diabetic kidney disease in the United States.

Proteomics International Managing Director Dr Richard Lipscombe said the relationship between the two organisations continues to strengthen. "Whilst the process of finalising the terms of the Exclusive Licence Agreement has taken the parties past the 28 February expiry date in the binding letter of intent [ASX 31 January], both organisations have already committed substantial resources towards a successful roll-out of PromarkerD across the USA and are still working actively together to achieve this."

The parties signed a binding and exclusive letter of intent in August to enter into an Exclusive Licence Agreement for the PromarkerD predictive test [ASX 9 August]. The Company will update the market once the Exclusive Licence Agreement has been signed.

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

News Provided by ABN Newswire